Sugarcane Biomass as a Source of Biofuel for Internal Combustion Engines (Ethanol and Acetone-Butanol-Ethanol): A Review of Economic Challenges

The objective of this review is to provide a deep overview of liquid biofuels produced from sugarcane bagasse and to address the economic challenges of an ethanol and acetone-butanol-ethanol blend in commercial processes. The chemistry of sugarcane bagasse is presented. Pretreatment technologies such as physical, chemical pretreatment, biological, and combination pretreatments used in the fermentation process are also provided and summarised. Different types of anaerobic bacteria Clostridia (yeast) are discussed to identify the ingredient best suited for sugarcane bagasse, which can assist the industry in commercializing ethanol and acetone-butanol-ethanol biofuel from biomass sugarcane. The use of an acetone-butanol-ethanol mixture and ethanol blend in internal combustion engines is also discussed. The literature then supports the proposal of the best operating conditions for fermentation to enhance ethanol and acetone-butanol-ethanol plant efficiency in the sugar waste industry and its application in internal combustion engines.</jats:p

Single-dose fluconazole versus standard 2-week therapy for oropharyngeal candidiasis in HIV-infected patients: a randomized, double-blind, double-dummy trial.

Contains fulltext : 70991.pdf (publisher's version ) (Open Access)BACKGROUND: Oropharyngeal candidiasis is the most common opportunistic infection affecting patients with human immunodeficiency virus (HIV) infection. Because of convenience, cost, and reluctance to complicate antiretroviral treatment regimens, single-dose fluconazole may be a favorable regimen for treatment of moderate to severe oropharyngeal candidiasis. We conducted a prospective, randomized, double-blind, placebo-controlled trial to compare the clinical and mycological responses, relapse rates, and safety of a single 750-mg dose and a 14-day course of treatment with fluconazole. METHODS: A total of 220 HIV-infected patients with clinical and mycological evidence of oropharyngeal candidiasis were randomly assigned in a 1:1 ratio to receive either a 750-mg single dose of orally administered fluconazole (110 patients) or 150 mg of orally administered fluconazole once per day for 2 weeks (110 patients). The primary efficacy analysis was based on clinical and mycological responses at the end of treatment. Secondary parameters were safety and relapse rate. RESULTS: Single-dose fluconazole was equivalent to a 14-day course of fluconazole in achieving clinical and mycological cure, with clinical cure rates of 94.5% and 95.5%, respectively (odds ratio, 0.825; 95% confidence interval, 0.244-2.789; P= .99), and mycological cure rates of 84.5% and 75.5%, respectively (odds ratio, 1.780; 95% confidence interval, 0.906-3.496; P= .129). Drug-related adverse events were uncommon and were not different between the treatment groups. CONCLUSION: A single dose of 750 mg of fluconazole was safe, well tolerated, and as effective as the standard 14-day fluconazole therapy in patients with HIV infection and acquired immunodeficiency syndrome who had oropharyngeal candidiasis coinfection

Nontoxic and Naturally Occurring Active Compounds as Potential Inhibitors of Biological Targets in <i>Liriomyza trifolii</i>

In recent years, novel strategies to control insects have been based on protease inhibitors (PIs). In this regard, molecular docking and molecular dynamics simulations have been extensively used to investigate insect gut proteases and the interactions of PIs for the development of resistance against insects. We, herein, report an in silico study of (disodium 5′-inosinate and petunidin 3-glucoside), (calcium 5′-guanylate and chlorogenic acid), chlorogenic acid alone, (kaempferol-3,7-di-O-glucoside with hyperoside and delphinidin 3-glucoside), and (myricetin 3′-glucoside and hyperoside) as potential inhibitors of acetylcholinesterase receptors, actin, α-tubulin, arginine kinase, and histone receptor III subtypes, respectively. The study demonstrated that the inhibitors are capable of forming stable complexes with the corresponding proteins while also showing great potential for inhibitory activity in the proposed protein-inhibitor combinations